Vaidya Sane Ayurved Laboratories Limited (NSE:MADHAVBAUG)
India · Delayed Price · Currency is INR 193.00
+1.10 (0.57%)
Jul 31, 2026, 3:02 PM IST
NSE:MADHAVBAUG Financials Overview
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Revenue Revenue Growth | 1,069 | 1,069 | 898.47 | 993.31 | 991.69 | 747.11 |
Revenue Growth | 9.10% | 18.99% | -9.55% | 0.16% | 32.74% | 42.92% |
Gross Profit Gross Profit Growth | 879.77 | 879.77 | 718.31 | 713.7 | 692.76 | 505.86 |
Operating Income Operating Income Growth | 92.88 | 92.88 | 93.48 | 13.62 | 52.59 | 48.18 |
Net Income Net Income Growth | 89.87 | 89.87 | 71.36 | 19.8 | 48.33 | 34.69 |
Earnings Per Share EPS Growth | 8.04 | 8.04 | 5.81 | 1.57 | 4.60 | 3.30 |
EPS Growth | 3.61% | 38.38% | 270.06% | -65.85% | 39.32% | 487.10% |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Hospital Activity Hospital Activity Growth | 286.26 | 286.26 | 231.99 | 217.38 | 198.77 | 156.95 |
Sale of Product Activity Sale of Product Activity Growth | 716.24 | 716.24 | 561.16 | 632.19 | 597.92 | 446.39 |
Unallocable Unallocable Growth | 66.57 | 66.57 | 77.95 | 123.9 | 195 | 143.72 |
Total Total Growth | 1,069 | 1,069 | 871.1 | 973.47 | 991.69 | 747.07 |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Investments Cash & Investments Growth | 230.65 | 230.65 | 173.16 | 183.59 | 155.59 | 191.68 |
Total Debt Total Debt Growth | 25.85 | 25.85 | 14.6 | 16.78 | 1.34 | 10.63 |
Net Cash (Debt) Net Cash Growth | 204.79 | 204.79 | 158.56 | 166.81 | 154.25 | 181.05 |
Net Cash Growth | 43.85% | 29.16% | -4.95% | 8.14% | -14.80% | - |
Net Cash Per Share Net Cash Per Share Growth | 18.32 | 18.32 | 12.85 | 13.52 | 14.67 | 17.22 |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 54.11 | 54.11 | 106.03 | -12.58 | 0.64 | -131.23 |
Capital Expenditures CapEx Growth | -78.79 | -78.79 | -84.47 | -111.5 | -69.79 | -31.72 |
Free Cash Flow Free Cash Flow Growth | -24.67 | -24.67 | 21.55 | -124.09 | -69.15 | -162.95 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Gross Margin | 82.29% | 82.29% | 79.95% | 71.85% | 69.86% | 67.71% |
Operating Margin | 8.69% | 8.69% | 10.40% | 1.37% | 5.30% | 6.45% |
Pretax Margin | 10.11% | 10.11% | 11.00% | 2.87% | 6.49% | 6.36% |
Profit Margin | 8.41% | 8.41% | 7.94% | 1.99% | 4.87% | 4.64% |
FCF Margin | -2.31% | -2.31% | 2.40% | -12.49% | -6.97% | -21.81% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 2, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 24.07 | 19.50 | 13.81 | 92.37 | 51.12 | 59.10 |
P/FCF Ratio | - | - | 45.70 | - | - | - |
PS Ratio | 1.90 | 1.64 | 1.10 | 1.84 | 2.49 | 2.74 |